SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors weigh significant cash holdings and potential acquisition strategies against a lack of immediate operational guidance following the latest earnings release. The community remains deeply polarized, with active debates centered on skepticism toward leadership, frustration over prolonged price stagnation, and persistent hopes for a major catalyst to trigger a move.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the market reacts to the release of preliminary clinical data from its siRNA pipeline for FSHD1 and DM1, alongside intense investor focus on the upcoming departure of FDA CBER lead Vinay Prasad. Community discussion is split between optimism regarding the potential for clinical breakthroughs to drive a short squeeze and skepticism over the company's long-term regulatory and commercial hurdles.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Mining Inc

Cipher Mining is drawing significant investor attention following a major expansion, marked by a 15-year hyperscale data center lease and a $200 million revolving credit facility. The community is actively debating the company's strategic pivot toward AI infrastructure while closely monitoring for further deal announcements, with many viewing the recent news as a fundamental re-rating for the stock.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is currently a central focus for traders debating whether the stock serves as a high-potential turnaround play driven by mortgage innovation and AI-integrated operations or a fundamentally challenged firm vulnerable to macroeconomic pressures. The community is actively split between bulls highlighting leadership's aggressive growth strategy and short-sellers betting on further downward price discovery amidst ongoing geopolitical uncertainty.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing significant investor attention as rumors of a potential SpaceX IPO intensify, with traders debating whether to buy the stock as a proxy for SpaceX and Anthropic exposure or to avoid it due to its high trading premium relative to net asset value. Community sentiment remains polarized, as bulls focus on the fund's high-profile private tech holdings, while bears emphasize its premium-to-NAV disconnect and the risks associated with holding a closed-end fund.

🌍 Introduction: A Legendary Icon, Reimagined for the Future The SEAMANIA Protocol, led by SEAMAN Cult, aims to revive one of SEGA Dreamcast's most iconic and best-selling game titles with AI integration—a worldwide cultural phenomenon that won numerous awards in the U.S. and Japan. More than just a game, SEAMAN was the world’s first AI-powered interactive experience, enabling voice-based conversations long before the AI revolution.    Now, SEAMAN returns not as a mere game, but as an advanced AI agent, blending nostalgia with cutting-edge technology. This human-faced fish is reborn as a deeply intelligent, emotionally responsiveAI, offering limitless customization and integration into the modern digital world.  With GenAI-powered customization, users can create their own SEAMAN AI, shaping it into a cherished lostone, a favorite celebrity, or even historical figures. This is no longer a game—it's an AI-driven personal companion and the digital evolution for human interaction.    🔥 Concept: The Wisdom of a Legendary AI-powered Companion At the core of the SEAMANIA Protocol lies the legendary Seaman—a mystical, human-faced fish endowed withancient wisdom and the ability to understand human language. More than just an AI, it is your trustedadvisor, best friend, therapist, personal cheerleader, witty conversationalist, intelligent guide, SEAMANIA is a life coach. Housed in your own digital aquarium, your SEAMAN AI reduces stress, combats loneliness, and guides humanity towards a brighter future. Imagine an AI companion that doesn’t just respond but truly understands, entertains, and supports you—blending humor, sarcasm, and wisdom.

SEAMANIA

SEAMANIA is trending as a highly speculative meme coin, with community members actively coordinating small-increment buying campaigns to trigger rapid price surges. Investors are drawing parallels to other volatile assets while expressing high-stakes optimism about the potential for massive percentage gains despite skepticism regarding its long-term viability.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is currently in the spotlight as investors process a combative rebuttal to a recent short report, with the community actively debating the company's long-term financial health versus the risks of activist short-selling tactics. While some investors remain highly convicted in the firm's fundamental growth trajectory and pending catalysts, the stock's recent volatility has triggered urgent calls for management to provide further clarity and reassure shareholders.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is facing intense selling pressure despite reporting record earnings, as investors react to concerns over increased capital expenditures and broader market volatility linked to geopolitical tensions. While the company maintains a strong fundamental outlook due to surging AI-driven memory demand, the community is deeply divided between those labeling the price action as institutional manipulation and those warning that the stock could see further downside toward the 300 level.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as investors weigh a confident outlook for 2026 and positive margin growth against ongoing concerns regarding market volatility and competitive pressure from retail giants. The community remains divided, with some traders optimistic about potential breakouts above key technical support levels, while others express frustration over recent price consolidation and the stock's sluggish performance despite steady business fundamentals.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is trending as investors digest a multibillion-dollar acquisition deal from Merck, fueling active discussions about the premium paid for its oncology pipeline and the broader M&A environment in biotech. Community chatter is split between congratulations for long-term holders witnessing a significant turnaround and skepticism regarding the valuation relative to future clinical risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merck &amp; Co. Inc. (MRK) has struck a multibillion-dollar deal to expand its oncology pipeline, agreeing to acquire clinical-stage biotech firm Terns Pharmaceuticals Inc. (TERN) for $53 per share in cash, at an approximate $6.7 billion valuation.&nbsp;The offer represents a 6% premium over Terns’ closing price as of Tuesday.&nbsp;Central to the acquisition is Terns’ experimental therapy, TERN-701, an oral treatment targeting specific mutations linked to chronic myeloid leukemia. The drug candidate is currently under evaluation in mid-stage clinical trials.&nbsp;Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/TERN">Terns Pharmaceuticals’ stock</a> traded over 4% higher in Wednesday’s premarket.&nbsp;Get updates to this developing story directly on Stocktwits.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck To Acquire Terns In $6.7B Deal – Signaling Fresh Push In Competitive Cancer Drug Race 

At the core of the deal is Terns’ investigational drug TERN-701, an oral therapy designed to address mutations associated with chronic myeloid leukemia.

Equity

At the core of the deal is Terns’ investigational drug TERN-701, an oral therapy designed to address mutations associated with chronic myeloid leukemia.


Frame 485.png

Get the daily email that keeps you tuned in and makes markets fun again.

cryptotwits - 800x800.png

Get the daily crypto email you’ll actually love to read. It's value-packed, data-driven, and seasoned with wit.

Frame 479.png

The best trade ideas and analysis from the Stocktwits community. Delivered daily by 8 pm ET.

Merck To Acquire Terns In $6.7B Deal – Signaling Fresh Push In Competitive Cancer Drug Race

Latest News